|  | Geographic variation | RHA group | ||||||
---|---|---|---|---|---|---|---|---|---|
Quality measure | Overall (n/N) | Winnipeg (n/N) | Other (n/N) | P value | Winnipeg | North Manitoba | South Manitoba | Middle Manitoba | P value |
 | (n/ N) | (n/ N) | (n/ N) | (n/ N) |  | ||||
Total colonic examination | 75.55% | 75.08% | 76.20% | 0.604 | 75.08% | 65.00% | 74.00% | 81.53% | 0.049 |
(1,230/1,628) | (705/939) | (525/689) | (705/939) | (26/40) | (296/400) | (203/249) | |||
Anastomotic leak/reoperation rate | 1.72% | 2.17% | 1.13% | 0.168 | 2.17% | 2.94% | 1.34% | 0.51% | 0.355a |
(21/1,220) | (15/691) | (6/529) | (15/691) | (1/34) | (4/298) | (1/197) | |||
Extent of lymphadenectomy | Â | Â | Â | Â | Â | Â | Â | Â | Â |
>12 lymph nodes | 68.75% | 69.07% | 68.31% | 0.749 | 69.07% | 58.97% | 72.42% | 63.22% | 0.054 |
(1,080/1,571) | (623/902) | (457/669) | (623/902) | (23/39) | (281/388) | Â | |||
Positive lymph node status | 45.47% | 45.76% | 45.09% | 0.790 | 45.76% | 48.72% | 43.48% | 47.11% | 0.781 |
(719/1,581) | (416/909) | (303/672) | (416/909) | (19/39) | (170/391) | (114/242) | |||
Medical oncology for rectal cancer | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Stage I to IV preoperative consultation | 13.15% | 12.90% | 13.51% | 0.866 | 12.90% | 28.57% | 13.51% | 11.94% | 0.668 |
(48/365) | (28/217) | (20/148) | (28/217) | (2/7) | (10/74) | (8/67) | |||
Stage II/III preoperative consultation | 16.25% | 14.48% | 18.95% | 0.359 | 14.48% | 40.00% | 22.73% | 13.04% | 0.250 |
(39/240) | (21/145) | (18/95) | (21/145) | (2/5) | (10/44) | (6/46) | |||
Stage II/III seen within 8 weeks of major surgery | 36.25% | 37.24% | 34.74% | 0.693 | 37.24% | 40.00% | 43.18% | 26.09% | 0.382 |
(87/240) | (54/145) | (33/95) | (54/145) | (2/5) | (19/44) | (12/46) | |||
Stage II/III seen within 16 weeks of major surgery | 63.33% | 63.45% | 63.16% | 0.964 | 63.45% | 60.00% | 77.27% | 50.00% | 0.065 |
(152/240) | (92/145) | (60/95) | (92/145) | (3/5) | (34/44) | (23/46) | |||
Radiation oncology for rectal cancer | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Stage I to IV preoperative consultation | 17.81% | 18.43% | 16.89% | 0.706 | 18.43% | 14.29% | 18.92% | 14.93% | 0.906 |
(65/365) | (40/217) | (25/148) | (40/217) | (1/7) | (14/74) | (10/67) | |||
Stage II/III preoperative consultation | 22.50% | 23.45% | 21.05% | 0.664 | 23.45% | 20.00% | 27.27% | 15.22% | 0.559 |
(54/240) | (34/145) | (20/95) | (34/145) | (1/5) | (12/44) | (7/46) | |||
Stage II/III seen within 8 weeks of major surgery | 31.25% | 33.79% | 27.37% | 0.294 | 33.79% | 0% | 27.27% | 30.43% | 0.384 |
(75/240) | (49/145) | (26/95) | (49/145) | (0/5) | (12/44) | (14/46) | |||
Stage II/III seen within 16 weeks of major surgery | 67.08% | 68.28% | 65.26% | 0.627 | 68.28% | 40.0% | 77.27% | 56.52% | 0.105 |
(161/240) | (99/145) | (62/95) | (99/145) | (2/5) | (34/44) | (26/46) | |||
Stage III colon cancer seen within 8 weeks of surgery | 27.27% | 27.35% | 27.15% | 0.966 | 27.35% | 55.56% | 28.92% | 20.34% | 0.160 |
(102/374) | (61/223) | (41/151) | (61/223) | (5/9) | (24/83) | (12/59) | |||
Stage III colon cancer seen within 16 weeks of surgery | 50.80% | 47.09% | 56.29% | 0.081 | 47.09% | 77.78% | 63.86% | 42.37% | 0.011 |
(190/374) | (105/223) | (85/151) | (105/223) | (7/9) | (53/83) | (25/59) | |||
30-day mortality | 3.75% | 4.05% | 3.34% | 0.506^ | 4.05% | 2.5% | 4.00% | 2.41% | 0.643^ |
(61/1,628) | (38/939) | (23/689) | (38/939) | (1/40) | (16/400) | (6/249) | |||
Surveillance colonoscopy within 12 months of surgery | 29.62% | 30.06% | 29.02% | 0.674 | 30.06% | 25.00% | 31.33% | 26.05% | 0.535 |
(410/1,384) | (242/805) | (168/579) | (242/805) | (8/32) | (104/332) | (56/215) | |||
Surveillance colonoscopy within 14 months of surgery | 45.37% | 47.22% | 42.81% | 0.106 | 47.22% | 32.26% | 45.12% | 40.76% | 0.167 |
 | (618/1,362) | (374/792) | (244/570) |  | (374/792) | (10/31) | (148/328) | (86/211) |  |